Horien Biotech (7814), a leading domestic manufacturer of high-end collagen medical devices, listed on the OTC market on the 16th at NT$28.45 per share. The stock price reached NT$32.15 in early trading, a 13.01% increase, initiating a honeymoon period. Horien Biotech Chairman Tsai Kuo-Tien stated that the listing is a significant milestone in the company's development history. In the future, the company will continue to deepen its global market penetration by leveraging top-grade medical-grade raw materials and groundbreaking high-end medical devices, building upon its existing dental and surgical channels.

 Horien Biotech, with its strong R&D capabilities and deep technological barriers, has recently delivered outstanding results in revenue performance, international certifications, global market expansion, and the establishment of a top-tier biomedical raw material supply chain. Driven by continued strong demand in the US, Taiwan, and overseas markets, Horien Biotech achieved a remarkable 209.29% revenue increase in June. This success is attributed not only to strong fundamentals but also to breakthrough progress in its overseas expansion.

 On July 7th, Horien Biotech successfully obtained three high-risk (highest level, Class 4) medical device market access licenses in Thailand, successfully entering the ASEAN high-end medical device market. Furthermore, the Philippines and Vietnam are also expected to obtain Class III medical device licenses soon, signifying that its important strategic layout in the Southeast Asian market is nearing completion. Moreover, the company's highly anticipated bio-ink innovative product is planned for official export to the European market by the end of this year, extending its international footprint from Asia to Europe and America, and is expected to see a surge in global revenue contributions.

 In the research and development of high-end innovative medical devices, Horien Biotech has achieved a disruptive world-class breakthrough. The company's independently developed "biodegradable ureteral stent" has successfully obtained a Taiwanese invention patent and is expected to soon obtain invention patents in the United States, Europe, and China. Currently, this innovative product has successfully completed sample development and has been officially delivered for animal testing.

Report Link:

Economic Daily News / Yan Ya-Fang